AbbVie
hepatitis C cocktail succeeds in late-stage study
Send a link to a friend
[June 24, 2015]
(Reuters) - AbbVie Inc said on
Wednesday that its hepatitis C cocktail Viekira Pak was effective
whether or not it was used in combination with the compound ribavirin
against the most common form of the disease, according to data from a
late-stage study.
|
Viekira Pak, a combination of the drugs Viekirax and Exviera, was
approved in December for use as both a standalone treatment and in
tandem with ribavirin, a broad-spectrum antiviral approved in 1998.
All the patients in the study showed a sustained response to Viekira
Pak as a standalone treatment after 12 weeks of treatment, AbbVie
said.
The late-stage study on which the U.S. Food and Drug Administration
based its decision to approve Viekira Pak in December showed it
cured 91-100 percent of all patients with the infection.
Viekira Pak is one of three treatments for the liver-scarring
disease fighting to corner the lion's share of the multi-billion
dollar market and competes with Gilead Sciences Inc's Sovaldi and
Harvoni, and Johnson & Johnson's Olysio.
(Reporting by Vidya L Nathan in Bengaluru, Editing by Simon
Jennings)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
![](../images/ads/current/Symphony_122313.png)
![](http://archives.lincolndailynews.com/2015/Jun/24/images/ads/current/june-revolving-ad.gif)
|